Sonnet BioTherapeutics Completes Enrollment In Phase 1 Study Of SON-1010 As Monotherapy For Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics has completed enrollment for its Phase 1 study of SON-1010, a targeted immune activation therapy for solid tumors. The company expects topline safety data by Q4 2024.
September 18, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics has completed enrollment for its Phase 1 study of SON-1010, a therapy aimed at treating solid tumors. The company anticipates topline safety data by Q4 2024.
The completion of enrollment in a Phase 1 study is a significant milestone for Sonnet BioTherapeutics, indicating progress in their clinical trials. The anticipation of topline safety data by Q4 2024 suggests potential future developments that could impact the company's stock positively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100